Singapore markets close in 6 hours 14 minutes
Straits Times Index
3,300.57 +7.88 (+0.24%) Nikkei
38,282.76 +8.71 (+0.02%) Hang Seng
18,027.03 +264.00 (+1.49%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,318.93 -2,428.62 (-4.06%) CMC Crypto 200
1,256.38 -82.69 (-8.79%)
Nektar Therapeutics (NKTR)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.4600 |
| Open | 1.4500 |
| Bid | 1.6200 x 1800 |
| Ask | 1.6600 x 1400 |
| Day's range | 1.4450 - 1.6500 |
| 52-week range | 0.4100 - 1.7500 |
| Volume | |
| Avg. volume | 2,607,742 |
| Market cap | 302.97M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
- PR Newswire
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata.
- PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023.
© 2024 Yahoo. All rights reserved.